Wolters Kluwer Medi-Span®

Name: Wolters Kluwer Medi-Span®
Brand: Wolters Kluwer

Wolters Kluwer Medi-Span® is a medication data and compendia suite that supplies drug identifiers and vocabularies, clinical screening modules, and drug pricing benchmarks for embedding into EHRs, pharmacy dispensing systems, and payer/PBM adjudication and analytics workflows.

Est 1836|Valuation $20.3B|Raised $840K

LinkedIn 357K|Website|Web traffic 3.0M|FTEs 21,000|HQ Alphen aan den Rijn, Netherlands

MarketsMaster Data Management (MDM)

01Competitive Landscape

Narrative comparison (where alternatives may excel)

- FDB vs Medi-Span: Both are major drug compendia. FDB is positioned on drug database + pricing/analysis tooling. If an organization is already standardized on FDB identifiers (e.g., GCN/GSN), switching to Medi-Span may introduce crosswalk and governance complexity. - Multum (Oracle/Cerner) vs Medi-Span: Multum is widely embedded in datasets and some health IT contexts; it can be attractive if the ecosystem already uses Multum codes and therapeutic categories. - Elsevier Gold Standard vs Medi-Span: Often chosen for integrated drug database + pricing applications; may appeal to organizations needing Elsevier’s broader content ecosystem.

Adoption / market presence signals (imperfect)

Wolters Kluwer asserts strong penetration among leading PBMs and EMR vendors; treat those as vendor claims unless validated.
Independent organizations (state health departments, researchers, and healthcare organizations) cite Medi-Span as a reference data source in public reports, which supports that it is commonly used.

	Medi-Span (Wolters Kluwer)	First Databank (FDB)	Elsevier Gold Standard Drug Database
Starting Price	Not public (licensed/quote)	Not public (licensed/quote)	Not public (licensed/quote)
Best For	Embedded drug data + identifiers (GPI), broad US drug file + pricing + clinical screening modules; enterprises needing consistency across payer/provider/pharmacy workflows	Enterprises wanting robust drug database ecosystem + pricing/analytics products; often benchmarked in KLAS reporting	Organizations wanting integrated drug database + drug pricing products; also used by researchers/analytics groups
Key Strength	Deep entrenchment in payer/PBM and pharmacy ecosystems; proprietary GPI taxonomy; multiple content sets and delivery formats (flat files/APIs)	Strong market presence; publishes multiple drug pricing/knowledge offerings; often highlighted in comparative ratings collateral	Broad drug database; pricing data and tooling (e.g., ProspectoRx) with a long market history
Key Weakness	Public transparency on pricing/security/compliance is limited; public review footprint is thin; vendor lock-in risk	Similar transparency limits; switching costs; licensing complexity	Similar licensing complexity; may differ in identifiers/groupers vs payer/PBM expectations

01Competitive Landscape

Narrative comparison (where alternatives may excel)

FDB vs Medi-Span: Both are major drug compendia. FDB is positioned on drug database + pricing/analysis tooling. If an organization is already standardized on FDB identifiers (e.g., GCN/GSN), switching to Medi-Span may introduce crosswalk and governance complexity.
Multum (Oracle/Cerner) vs Medi-Span: Multum is widely embedded in datasets and some health IT contexts; it can be attractive if the ecosystem already uses Multum codes and therapeutic categories.
Elsevier Gold Standard vs Medi-Span: Often chosen for integrated drug database + pricing applications; may appeal to organizations needing Elsevier’s broader content ecosystem.

Adoption / market presence signals (imperfect)

Wolters Kluwer asserts strong penetration among leading PBMs and EMR vendors; treat those as vendor claims unless validated.
Independent organizations (state health departments, researchers, and healthcare organizations) cite Medi-Span as a reference data source in public reports, which supports that it is commonly used.

	Medi-Span (Wolters Kluwer)	First Databank (FDB)	Elsevier Gold Standard Drug Database
Starting Price	Not public (licensed/quote)	Not public (licensed/quote)	Not public (licensed/quote)
Best For	Embedded drug data + identifiers (GPI), broad US drug file + pricing + clinical screening modules; enterprises needing consistency across payer/provider/pharmacy workflows	Enterprises wanting robust drug database ecosystem + pricing/analytics products; often benchmarked in KLAS reporting	Organizations wanting integrated drug database + drug pricing products; also used by researchers/analytics groups
Key Strength	Deep entrenchment in payer/PBM and pharmacy ecosystems; proprietary GPI taxonomy; multiple content sets and delivery formats (flat files/APIs)	Strong market presence; publishes multiple drug pricing/knowledge offerings; often highlighted in comparative ratings collateral	Broad drug database; pricing data and tooling (e.g., ProspectoRx) with a long market history
Key Weakness	Public transparency on pricing/security/compliance is limited; public review footprint is thin; vendor lock-in risk	Similar transparency limits; switching costs; licensing complexity	Similar licensing complexity; may differ in identifiers/groupers vs payer/PBM expectations